Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

about

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.

P2860

Q50872004-96A9CCCB-1283-420D-A255-E1039E8C9A5C Q51066079-E3A58D9A-1060-46F5-92D6-41756C4C8C32 Q52717006-E4BCC821-FBD5-459C-9C5C-D1C7D19E4CFA

P2860

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

Item

http://www.wikidata.org/entity/Q36018006

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@ast

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@en

type

Item

label

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@ast

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@en

prefLabel

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@ast

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@en

P1476

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

@en

P2093

Andrew Chang

http://www.w3.org/2001/XMLSchema#string

Meidong Zhu

http://www.w3.org/2001/XMLSchema#string

Thomas Hong

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

The biology of VEGF and its receptors

Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

Leukocyte-mediated endothelial cell injury and death in the diabetic retina

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema.

Ocular oxygenation and the treatment of diabetic retinopathy.

Choroidal neovascularization after laser photocoagulation for diabetic macular edema.

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

P2888

s00125-016-3974-8

P304

1594-1608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00125-016-3974-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bobak Bahrami

P577

2016-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27179659

http://www.w3.org/2001/XMLSchema#string

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

about

P2860

P2860

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698